Damora Therapeutics is trading 5.75% up at $33.29 as traders refocus on the company's near-term blood-disorder pipeline milestones and strong cash runway.
- Momentum is building ahead of expected mid-2026 regulatory submissions for lead antibody program DMR-001.
- The move appears driven by investor positioning and broader strength in growth and biotech names, with no new company announcements released today.